Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Opaganib - RedHill Biopharma

Next Previous
X
Search
Drug Profile

Opaganib - RedHill Biopharma

Alternative Names: ABC-294640; YELIVA

Latest Information Update: 24 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Apogee Biotechnology Corporation
  • Developer Apogee Biotechnology Corporation; Medical University of South Carolina; RedHill Biopharma; University of Louisville
  • Class Adamantanes; Amides; Anti-inflammatories; Antihypoglycaemics; Antineoplastics; Antirheumatics; Antithrombotics; Antivirals; Chlorobenzenes; Obesity therapies; Pyridines; Small molecules
  • Mechanism of Action Sphingosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma; Cholangiocarcinoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer; Inflammation

Highest Development Phases

  • Phase II/III COVID-19 pneumonia
  • Phase II Cholangiocarcinoma; Prostate cancer
  • Preclinical Acute radiation syndrome; COVID 2019 infections; Ebola virus infections; Influenza A virus infections; Obesity; Radiation injuries; Renal fibrosis; SARS-CoV-2 acute respiratory disease; Type 2 diabetes mellitus
  • Suspended Liver cancer
  • No development reported Cancer; Inflammatory bowel diseases; Osteoarthritis; Rheumatoid arthritis; Solid tumours
  • Discontinued Multiple myeloma

Most Recent Events

  • 22 Oct 2024 RedHill Biopharma and Duke University School of Medicine agree to co-develop Opaganibin for Lung injury (Phosgene inhalation injury)
  • 30 Sep 2024 9426589: Patent protection for Identification of biomarkers for coronavirus pneumonia and post hoc data, no updates
  • 26 Aug 2024 Opaganib receives Orphan Drug status for neuroblastoma in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top